Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study
Frontiers in Cellular and Infection Microbiology · 29.04.2026 · 16
DOI: 10.3389/fcimb.2026.1802657 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 29.04.2026. Verfasst von Hongmei Gong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Interferon-alpha, Antiviral Agents, Hepatitis B, Chronic, Polyethylene Glycols. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Hepatitis B surface antigen (HBsAg) clearance is a key milestone for functional (clinical) cure of chronic hepatitis B virus (HBV) infection. However, data on the efficacy and safety of pegylated interferon alpha (Peg-IFNα) for HBsAg clearance in postpartum women with chronic HBV infection remain scarce. This study aimed to prospectively evaluate the efficacy and safety of Peg-IFNα in promoting HBsAg clearance in this specific population.
Methods
A total of 263 HBV-infected postpartum women with a baseline HBsAg levels ≤3000 IU/mL were enrolled. Based on patient preference, they were assigned to either the Peg-IFNα group (n=62, receiving Peg-IFNα monotherapy or combination therapy with nucleos(t)ide analogs [NAs]) or the control group (n=201, receiving NAs or follow-up only). The duration of Peg-IFNα treatment was ≥48 weeks. Propensity score matching (PSM) was performed to balance baseline characteristics. The primary endpoints were both HBsAg clearance rate and the magnitude of HBsAg decline.
Results
At week 48, the Peg-IFNα group had significantly higher HBsAg clearance (29.03% [18/62]) and seroconversion rates (27.42% [17/62]) than the control group (both 0%, P < 0.001). Post-PSM, the Peg-IFNα group still had a significantly higher HBsAg clearance/seroconversion rate (30.43% [14/46]) versus the control group (0%, P < 0.001). Subgroup analysis showed that patients with baseline HBsAg < 1000 IU/mL had higher clearance rates (pre-PSM: 39.02% [16/41]; post-PSM: 40.00% [12/30]). Receiver operating characteristic (ROC) curve analysis identified a ≥ 99.2% HBsAg reduction from baseline to week 12 as a strong predictor of week 48 HBsAg clearance (AUC ≥0.9; sensitivity =0.818; specificity= 1.000).
Conclusion
Peg-IFNα treatment can achieve high rates of HBsAg clearance and seroconversion in postpartum women with chronic HBV infection. The postpartum period represents a unique and favorable immune window for interferon-based intervention, and patients with baseline HBsAg <1000 IU/mL derive particular benefit from this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, The First Affiliated Hospital of Army Medical University, Chongqing, China.
- Department of Infectious Diseases, The Third Affiliated Hospital of Chongqing Medical University (Fangda Hospital), Chongqing, China.
- Department of Infectious Diseases and Hepatology, People's Hospital of Banan District, Chongqing, China.
- Department of Infectious Diseases, People's Hospital of Hechuan District, Chongqing, China.
- Department of Infectious Diseases, Jiangbei Branch of The First Affiliated Hospital of Army Medical University, Chongqing, China.
Zitieren
APA
Gong, H., Liu, M., Zhang, X., Sun, W., Deng, H., Liu, W., Wu, Y., Deng, G., Xia, J., Mao, Q., & Jiang, L. (2026). Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1802657
Vancouver
Gong H, Liu M, Zhang X, Sun W, Deng H, Liu W, et al. Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1802657
BibTeX
@article{Gong2026,
author = {Gong, Hongmei and Liu, Ming and Zhang, Xuqing and Sun, Wei and Deng, Hongli and Liu, Wei and Wu, Yi and Deng, Guohong and Xia, Jie and Mao, Qing and Jiang, Li},
title = {Efficacy of pegylated interferon alpha in treating postpartum women with chronic hepatitis B virus infection: a multicenter prospective study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1802657}
}
EUVIMED